Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Price:
0.87
USD
-3.33%
Market Cap:
$9.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
US |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of BCLI.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BCLI
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
BCLI Competitors Multiples
Brainstorm Cell Therapeutics Inc Competitors
Brainstorm Cell Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
9.6m USD | 0 | -0.9 | -0.8 | -0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
376.8B USD | 6.3 | 91.6 | 15.1 | 21 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
361.6B USD | 111.3 | -1 738.3 | 16 147.7 | -1 823.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.1B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.2B USD | 5.8 | 20.1 | 12.6 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.6B USD | 9.4 | 28.6 | 21.5 | 22.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.7 | 18 | 13.4 | 15.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD | 3.1 | 34.8 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
